BONESUPPORT™ Announces CERAMENT® Focused Research Collaboration with Rigshospitalet, Copenhagen University Hospital

23rd September 2020

BONESUPPORT™ Announces 20,000 Patients Now Treated with CERAMENT®

23rd September 2020

BONESUPPORT™ Announces Appointment of Life Sciences Industry Veteran, Richard Davies, as New Chief Executive Officer

23rd September 2020

BONESUPPORT™ Reports Expansion of Company’s CERAMENT® Drug Eluting Procedure Registry

23rd September 2020

BONESUPPORT® Announces Availability in Europe of CERAMENT™|G in 5 mL Volume to Address Growing Market Demand

23rd September 2020

BONESUPPORT™ Announces Nature Publication of Pre-Clinical Study Highlighting CERAMENT®’s Attractive Bone Remodeling Properties and as a Local Drug Delivery Platform for Bone Disease

23rd September 2020

BONESUPPORT™ Receives FDA Approval to Initiate IDE Clinical Study

23rd September 2020

BONESUPPORT™‘s CERAMENT®|G and CERAMENT® V to be Featured Extensively at the 35th Annual Meeting of the European Bone & Joint Infection Society (EBJIS) in Oxford, UK

23rd September 2020

BONESUPPORT™‘s CERAMENT®|G Highly Effective Adjunct in the Single Stage Surgical Management of Chronic Osteomyelitis

23rd September 2020

BONESUPPORT™ Raises $37 Million (SEK 327 million) to Drive Product Sales and Deliver Further Value From CERAMENT® Injectable Drug Eluting Bioceramic Platform

23rd September 2020